Back to Search
Start Over
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib
- Source :
- Blood
- Publication Year :
- 2020
-
Abstract
- E1912 was a randomized phase 3 trial comparing indefinite ibrutinib plus 6 cycles of rituximab (IR) to 6 cycles of fludarabine, cyclophosphamide, and rituximab (FCR) in untreated younger patients with CLL. We describe measurable residual disease (MRD) levels in E1912 over time and correlate them with clinical outcome. Undetectable MRD rates (
- Subjects :
- Male
medicine.medical_specialty
Neoplasm, Residual
Cyclophosphamide
Immunology
Disease
Biochemistry
Gastroenterology
chemistry.chemical_compound
Piperidines
hemic and lymphatic diseases
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Progression-free survival
Protein Kinase Inhibitors
Lymphoid Neoplasia
business.industry
Surrogate endpoint
Adenine
Hazard ratio
Cell Biology
Hematology
Middle Aged
Flow Cytometry
Prognosis
Leukemia, Lymphocytic, Chronic, B-Cell
Progression-Free Survival
Fludarabine
body regions
Treatment Outcome
chemistry
Ibrutinib
Rituximab
Female
business
Vidarabine
medicine.drug
Subjects
Details
- ISSN :
- 15280020
- Volume :
- 138
- Issue :
- 26
- Database :
- OpenAIRE
- Journal :
- Blood
- Accession number :
- edsair.doi.dedup.....01fef2249d64c4a1879578fd1fc318d4